A Systematic Review and Meta-analysis on Safety and Effectiveness of Extended-interval Dosing of Natalizumab in Patients with Relapsing-remitting Multiple Sclerosis: Is There Any Value in The Cost of Treatment? (PP-08)
Background: Standard-interval dosing (SID) of natalizumab (i.e., 300 mg every 28 days) is approved for patients with relapsing-remitting multiple sclerosis (RRMS). Since patients taking natalizumab are at increased risk of developing progressive multifocal leukoencephalopathy (PML), some neurologist...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Iran University of Medical Sciences
2023-01-01
|
| Series: | Neurology Letters |
| Subjects: | |
| Online Access: | https://www.neurologyletters.com/article_185415_d41d8cd98f00b204e9800998ecf8427e.pdf |
| _version_ | 1827389150057201664 |
|---|---|
| author | Taraneh Mousavi Behzad Fatemi Shekoufeh Nikfar Mohammad Ali Sahraian |
| author_facet | Taraneh Mousavi Behzad Fatemi Shekoufeh Nikfar Mohammad Ali Sahraian |
| author_sort | Taraneh Mousavi |
| collection | DOAJ |
| description | Background: Standard-interval dosing (SID) of natalizumab (i.e., 300 mg every 28 days) is approved for patients with relapsing-remitting multiple sclerosis (RRMS). Since patients taking natalizumab are at increased risk of developing progressive multifocal leukoencephalopathy (PML), some neurologists may consider extended-interval dosing (EID) regimen instead. However, there has been by far no consensus on the safety and effectiveness of the EID regimen.
Methods: We searched MEDLINE, EMBASE, Scopus, Web of Science, Cochrane Database of Systematic Reviews, and Clinical trials.gov until March 30, 2023. To evaluate the safety and effectiveness of EID (> 5 weeks) and SID (≤ 5 weeks) regimens of natalizumab, studies on RRMS patients aged> 18 years old were included. The primary effectiveness outcome was pooled Mean Difference (MD) of annualized relapse rate (ARR), and the primary safety outcome was pooled Risk Ratio (RR) of PML development. Additional outcomes were the pooled MD of the expanded disability status scale (EDSS) and pooled RR of new MRI activity.
Results: Of the 712 publications identified, 11 studies involving 9397 patients were included. The median duration of follow-up was 23 months. Pooled MD of ARR was -0.001 (95% CI, -0.05 to 0.05; P-value = 0.95) indicating that there is no statistically significant difference between SID and EID regimens of natalizumab in terms of effectiveness. This is while, pooled RR of PML was 0.49 (95% CI, 0.28 to 0.87; P-value = 0.01) suggesting statistically significant superiority of natalizumab EID over the SID regimen in RRMS.
Conclusion: Compared to the SID regimen, extending the dosing interval of natalizumab was associated with a statistically meaningful reduced risk of PML, and probably lower cost of the treatment, while preserving the treatment effectiveness. However, due to the limited number of included populations, any interpretation of the present study's results in clinical practice should be done with caution. |
| first_indexed | 2024-03-08T16:30:17Z |
| format | Article |
| id | doaj.art-6fc608a2389642eaba5491b68ecd4f41 |
| institution | Directory Open Access Journal |
| issn | 2821-1723 |
| language | English |
| last_indexed | 2024-03-08T16:30:17Z |
| publishDate | 2023-01-01 |
| publisher | Iran University of Medical Sciences |
| record_format | Article |
| series | Neurology Letters |
| spelling | doaj.art-6fc608a2389642eaba5491b68ecd4f412024-01-06T08:20:06ZengIran University of Medical SciencesNeurology Letters2821-17232023-01-012Supplementary 1 (20th Iranian Multiple Sclerosis Congress)185415A Systematic Review and Meta-analysis on Safety and Effectiveness of Extended-interval Dosing of Natalizumab in Patients with Relapsing-remitting Multiple Sclerosis: Is There Any Value in The Cost of Treatment? (PP-08)Taraneh Mousavi0Behzad Fatemi1Shekoufeh Nikfar2Mohammad Ali Sahraian31. Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran, Iran 2. Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences, Tehran, IranDepartment of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IranDepartment of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IranMultiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, IranBackground: Standard-interval dosing (SID) of natalizumab (i.e., 300 mg every 28 days) is approved for patients with relapsing-remitting multiple sclerosis (RRMS). Since patients taking natalizumab are at increased risk of developing progressive multifocal leukoencephalopathy (PML), some neurologists may consider extended-interval dosing (EID) regimen instead. However, there has been by far no consensus on the safety and effectiveness of the EID regimen. Methods: We searched MEDLINE, EMBASE, Scopus, Web of Science, Cochrane Database of Systematic Reviews, and Clinical trials.gov until March 30, 2023. To evaluate the safety and effectiveness of EID (> 5 weeks) and SID (≤ 5 weeks) regimens of natalizumab, studies on RRMS patients aged> 18 years old were included. The primary effectiveness outcome was pooled Mean Difference (MD) of annualized relapse rate (ARR), and the primary safety outcome was pooled Risk Ratio (RR) of PML development. Additional outcomes were the pooled MD of the expanded disability status scale (EDSS) and pooled RR of new MRI activity. Results: Of the 712 publications identified, 11 studies involving 9397 patients were included. The median duration of follow-up was 23 months. Pooled MD of ARR was -0.001 (95% CI, -0.05 to 0.05; P-value = 0.95) indicating that there is no statistically significant difference between SID and EID regimens of natalizumab in terms of effectiveness. This is while, pooled RR of PML was 0.49 (95% CI, 0.28 to 0.87; P-value = 0.01) suggesting statistically significant superiority of natalizumab EID over the SID regimen in RRMS. Conclusion: Compared to the SID regimen, extending the dosing interval of natalizumab was associated with a statistically meaningful reduced risk of PML, and probably lower cost of the treatment, while preserving the treatment effectiveness. However, due to the limited number of included populations, any interpretation of the present study's results in clinical practice should be done with caution.https://www.neurologyletters.com/article_185415_d41d8cd98f00b204e9800998ecf8427e.pdfnatalizumabmultiple sclerosis |
| spellingShingle | Taraneh Mousavi Behzad Fatemi Shekoufeh Nikfar Mohammad Ali Sahraian A Systematic Review and Meta-analysis on Safety and Effectiveness of Extended-interval Dosing of Natalizumab in Patients with Relapsing-remitting Multiple Sclerosis: Is There Any Value in The Cost of Treatment? (PP-08) Neurology Letters natalizumab multiple sclerosis |
| title | A Systematic Review and Meta-analysis on Safety and Effectiveness of Extended-interval Dosing of Natalizumab in Patients with Relapsing-remitting Multiple Sclerosis: Is There Any Value in The Cost of Treatment? (PP-08) |
| title_full | A Systematic Review and Meta-analysis on Safety and Effectiveness of Extended-interval Dosing of Natalizumab in Patients with Relapsing-remitting Multiple Sclerosis: Is There Any Value in The Cost of Treatment? (PP-08) |
| title_fullStr | A Systematic Review and Meta-analysis on Safety and Effectiveness of Extended-interval Dosing of Natalizumab in Patients with Relapsing-remitting Multiple Sclerosis: Is There Any Value in The Cost of Treatment? (PP-08) |
| title_full_unstemmed | A Systematic Review and Meta-analysis on Safety and Effectiveness of Extended-interval Dosing of Natalizumab in Patients with Relapsing-remitting Multiple Sclerosis: Is There Any Value in The Cost of Treatment? (PP-08) |
| title_short | A Systematic Review and Meta-analysis on Safety and Effectiveness of Extended-interval Dosing of Natalizumab in Patients with Relapsing-remitting Multiple Sclerosis: Is There Any Value in The Cost of Treatment? (PP-08) |
| title_sort | systematic review and meta analysis on safety and effectiveness of extended interval dosing of natalizumab in patients with relapsing remitting multiple sclerosis is there any value in the cost of treatment pp 08 |
| topic | natalizumab multiple sclerosis |
| url | https://www.neurologyletters.com/article_185415_d41d8cd98f00b204e9800998ecf8427e.pdf |
| work_keys_str_mv | AT taranehmousavi asystematicreviewandmetaanalysisonsafetyandeffectivenessofextendedintervaldosingofnatalizumabinpatientswithrelapsingremittingmultiplesclerosisisthereanyvalueinthecostoftreatmentpp08 AT behzadfatemi asystematicreviewandmetaanalysisonsafetyandeffectivenessofextendedintervaldosingofnatalizumabinpatientswithrelapsingremittingmultiplesclerosisisthereanyvalueinthecostoftreatmentpp08 AT shekoufehnikfar asystematicreviewandmetaanalysisonsafetyandeffectivenessofextendedintervaldosingofnatalizumabinpatientswithrelapsingremittingmultiplesclerosisisthereanyvalueinthecostoftreatmentpp08 AT mohammadalisahraian asystematicreviewandmetaanalysisonsafetyandeffectivenessofextendedintervaldosingofnatalizumabinpatientswithrelapsingremittingmultiplesclerosisisthereanyvalueinthecostoftreatmentpp08 AT taranehmousavi systematicreviewandmetaanalysisonsafetyandeffectivenessofextendedintervaldosingofnatalizumabinpatientswithrelapsingremittingmultiplesclerosisisthereanyvalueinthecostoftreatmentpp08 AT behzadfatemi systematicreviewandmetaanalysisonsafetyandeffectivenessofextendedintervaldosingofnatalizumabinpatientswithrelapsingremittingmultiplesclerosisisthereanyvalueinthecostoftreatmentpp08 AT shekoufehnikfar systematicreviewandmetaanalysisonsafetyandeffectivenessofextendedintervaldosingofnatalizumabinpatientswithrelapsingremittingmultiplesclerosisisthereanyvalueinthecostoftreatmentpp08 AT mohammadalisahraian systematicreviewandmetaanalysisonsafetyandeffectivenessofextendedintervaldosingofnatalizumabinpatientswithrelapsingremittingmultiplesclerosisisthereanyvalueinthecostoftreatmentpp08 |